

ARTICLE

# Origin of cytoplasmic GDP-fucose determines its contribution to glycosylation reactions

Paulina Sosicka<sup>1</sup>, Bobby G. Ng<sup>1</sup>, Lauren E. Pepi<sup>2</sup>, Asif Shajahan<sup>2</sup>, Maurice Wong<sup>3</sup>, David A. Scott<sup>4</sup>, Kenjiro Matsumoto<sup>2</sup>, Zhi-Jie Xia<sup>1</sup>, Carlito B. Lebrilla<sup>3</sup>, Robert S. Haltiwanger<sup>2</sup>, Parastoo Azadi<sup>2</sup>, and Hudson H. Freeze<sup>1</sup>

**Biosynthesis of macromolecules requires precursors such as sugars or amino acids, originating from exogenous/dietary sources, reutilization/salvage of degraded molecules, or de novo synthesis. Since these sources are assumed to contribute to one homogenous pool, their individual contributions are often overlooked. Protein glycosylation uses monosaccharides from all the above sources to produce nucleotide sugars required to assemble hundreds of distinct glycans. Here, we demonstrate that cells identify the origin/heritage of the monosaccharide, fucose, for glycosylation. We measured the contribution of GDP-fucose from each of these sources for glycan synthesis and found that different fucosyltransferases, individual glycoproteins, and linkage-specific fucose residues identify and select different GDP-fucose pools dependent on their heritage. This supports the hypothesis that GDP-fucose exists in multiple, distinct pools, not as a single homogenous pool. The selection is tightly regulated since the overall pool size remains constant. We present novel perspectives on monosaccharide metabolism, which may have a general applicability.**

## Introduction

Biosynthesis of macromolecules requires precursors such as sugars or amino acids, which are derived alternatively from the diet (exogenous precursors) via reutilization (salvage) of degraded molecules or by de novo synthesis. Often, salvaged and exogenous precursors are thought to intermingle and are treated as homogenous sources, but it is important to emphasize that these two pathways must be considered separately. Exogenous molecules originate from the diet and enter the cell via specific transporter(s) as single molecules, while salvaged precursors are recycled from macromolecules following their lysosomal or proteasomal degradation. The common assumption is that the heritage of these precursors is of little importance since they contribute to a common, homogenous pool intended for different cellular processes.

Monosaccharides are used by cells to produce energy and for the synthesis of macromolecules. Glycosylation is the process by which carbohydrates are covalently attached to a target macromolecule utilizing monosaccharides from varying sources to produce nucleotide sugars, substrates that are further used to assemble distinct glycans (Varki et al., 2015). Under physiological concentrations, a detailed analysis of mannose metabolism in human fibroblasts demonstrated that neither gluconeogenesis, glycogen, nor mannose salvaged from glycoprotein degradation

contributed to mannose found in N-glycans. In contrast, cells efficiently use exogenous mannose for N-glycan biosynthesis (Ichikawa et al., 2014). How cells determine which portion of a monosaccharide pool is directly incorporated into glycans and which fraction is utilized for other cellular processes, i.e., as an energy source, remains unknown. Although efforts have been made to study how these different pathways contribute to nucleotide sugar biosynthesis, they were never investigated simultaneously. Does glycosylation recognize the heritage of the monosaccharide? If yes, how is this regulated? We believe these questions are significant because dietary monosaccharide supplements are successful therapies for some disorders of glycosylation (Verheijen et al., 2020) and even for cancer (Gonzalez et al., 2018).

In humans, fucose is incorporated into glycans using GDP-fucose as a nucleotide sugar donor (Schneider et al., 2017). It can be synthesized directly from exogenous fucose (fucose<sup>Ex</sup>) or from fucose salvaged from glycoprotein degradation (fucose<sup>Sal</sup>; Coffey et al., 1964; Kaufman and Ginsburg, 1968). Both require subsequent actions of fucokinase (FCSK) and fucose-1-phosphate guanylyltransferase (FPGT) to “activate” fucose (Ishihara et al., 1968). Alternatively, GDP-fucose can be produced de novo from either mannose (fucose<sup>Man</sup>) or glucose (fucose<sup>Glc</sup>). In this

<sup>1</sup>Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA; <sup>2</sup>Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia; <sup>3</sup>Department of Chemistry, University of California Davis, Davis, CA; <sup>4</sup>Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.

Correspondence to Paulina Sosicka: [psosicka@sbpdiscovery.org](mailto:psosicka@sbpdiscovery.org); Hudson H. Freeze: [HUDSON@SBPDISCOVERY.ORG](mailto:HUDSON@SBPDISCOVERY.ORG).

© 2022 Sosicka et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see <http://www.rupress.org/terms/>). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at <https://creativecommons.org/licenses/by-nc-sa/4.0/>).

process, GDP-mannose is converted to GDP-fucose in a three-step reaction catalyzed by two enzymes—GDP-mannose 4,6-dehydratase (GMDS) and GDP-fucose synthetase (GFUS; Ginsburg, 1960; Fig. 1 A). In 1975, isotope-dilution studies using  $^3\text{H}$ -fucose at a single concentration of 0.3  $\mu\text{M}$  demonstrated that only  $\sim 10\%$  of GDP-fucose in HeLa cells originated from fucose<sup>Ex</sup>, while  $\sim 90\%$  was assumed to be synthesized de novo (Yurchenco and Atkinson, 1975; Yurchenco and Atkinson, 1977). This method assumed that the radiolabeled component is a metabolic tracer, making little contribution to the overall products. The contribution of fucose<sup>Sal</sup> (or other monosaccharides) was never addressed.

GDP-fucose incorporation into glycoconjugates requires its delivery into the Golgi apparatus and ER. This process is mediated by two nucleotide sugar transporters, one of them is the major provider of the Golgi GDP-fucose, while the other delivers this nucleotide sugar to the ER (Lu et al., 2010; Lühn et al., 2001). In humans, there are 13 known fucosyltransferases (FUTs), which mostly localize to the Golgi, where they are engaged in fucosylation of N- and O-glycans, as well as glycolipids (Schneider et al., 2017). Although many of them have overlapping substrate specificities, there is only one enzyme, FUT8, that adds  $\alpha$ -1-6 fucose to the N-glycan chitobiose core (Yang and Wang, 2016). There are two known FUTs localized to the ER, and they add O-fucose directly to Ser/Thr residues of distinct glycoproteins (Schneider et al., 2017).

Using fucose as a model monosaccharide, we evaluated the simultaneous contributions of exogenous, salvaged, and de novo-produced fucose to glycosylation. At physiological levels of exogenous monosaccharides, our results show that cells can tightly regulate multiple pools of GDP-fucose and can recognize their heritage for glycan synthesis.

## Results

### Cells selectively utilize fucose from different sources

We measured the relative contribution of fucose<sup>Ex</sup> and fucose from the de novo pathway by incubating cells with differentially labeled  $^{13}\text{C}$ -monosaccharides. N-glycan-associated fucose synthesized from exogenous glucose (5 mM), mannose (50  $\mu\text{M}$ ), and directly from fucose (0–50  $\mu\text{M}$ ) was determined following acid hydrolysis and analysis by GC-MS (Fig. S1, A–C). Their contributions are assumed to reflect their abundance in the GDP-fucose pool since it is the only known source for glycan synthesis. Using this GC-MS method, we repeated the HeLa cell experiments (Yurchenco and Atkinson, 1975; Yurchenco and Atkinson, 1977) and confirmed the dominant role of the de novo pathway at very low fucose concentration  $\leq 2.5$   $\mu\text{M}$ . In the absence of fucose<sup>Ex</sup>  $\sim$ five times more N-glycan-associated fucose originates from  $^{13}\text{C}$ -glucose than from  $^{13}\text{C}$ -mannose (Fig. 1, B and C; and Fig. S1 D). Since the physiological concentration of mannose (50  $\mu\text{M}$ ) is  $\sim 100$  times less than glucose (5 mM), mannose is utilized more efficiently for fucosylation compared to glucose, as previously seen for mannose in N-glycans (Ichikawa et al., 2014). However, GDP-fucose produced by the de novo pathway is completely suppressed by fucose<sup>Ex</sup>, which becomes the major source of N-glycan-associated fucose, when it is added to  $\sim 30$ –50  $\mu\text{M}$  (Fig. 1, B and C). The same pattern was

seen in nine different cell lines of varying tissue origin (Fig. 1, B and C; and Fig. S1 D). To eliminate possible kinetic isotope effects, we exchanged the number and location of  $^{13}\text{C}$  carbons between glucose, mannose, and fucose, but the results remained unchanged (Fig. 1 B and Fig. S1 F). Labeling time (12 and 48 h) did not affect our results either (Fig. 1 B and Fig. S1 H).

The preference for fucose<sup>Ex</sup> might be explained by an increase in the total GDP-fucose pool. Therefore, we isolated nucleotide sugars from HepG2, Huh7, and CHO cells grown in the absence or presence of 50  $\mu\text{M}$  fucose and demonstrated that the treatment does not increase the total cytosolic concentration of GDP-fucose (Fig. 1 D and Fig. S2). Therefore, it appears that GDP-fucose originating from fucose<sup>Ex</sup> suppresses de novo GDP-fucose synthesis. The most likely explanation is the known feedback inhibition of the de novo pathway enzyme GMDS (Fig. 1 A) by GDP-fucose as previously shown for *Escherichia coli* and human enzymes (Kornfeld and Ginsburg, 1966; Sullivan et al., 1998).

The ratio of glucose to mannose contributions to N-glycan-associated mannose varies from 5:1 to 3:1 between different cell lines (Ichikawa et al., 2014). This ratio does not change upon fucose<sup>Ex</sup> titration (Fig. S3). Therefore, we expected that this would also be true for their contribution to N-glycan-associated fucose. However, the contribution of fucose<sup>Glc</sup> preferentially decreases compared to that of fucose<sup>Man</sup>. Between 0 and 30  $\mu\text{M}$  fucose<sup>Ex</sup>, the ratio changes from  $\sim 6:1$  to 3:1 in HepG2 cells (Fig. 1 E; and Fig. S1, E, G, and I). This is not compatible with a single homogenous GDP-mannose pool serving as a substrate for GMDS. Therefore, we believe there are at least two GDP-mannose pools.

### Exogenous fucose has little impact on the use of salvaged fucose

To measure fucose salvage from degraded glycans, we focused on newly synthesized, secreted, and fucosylated N-glycoproteins. This approach allowed us to simultaneously study all four sources of N-glycan-associated fucose: fucose<sup>Man</sup>, fucose<sup>Glc</sup>, fucose<sup>Ex</sup>, and fucose<sup>Sal</sup>. To distinguish fucose<sup>Sal</sup> from fucose<sup>Ex</sup>, we first pre-labeled cells for 11 d with  $^{13}\text{C}$ -UL-Fucose (M+6), which replaced over 90% of  $^{12}\text{C}$ -fucose, before labeling with exogenous  $^{13}\text{C}$ -6-fucose (M+1).

To ensure that the secreted material predominantly contains newly synthesized proteins rather than those released by surface proteolysis, we pulse-labeled HepG2 cells for 2 h with S<sup>35</sup> Met to assess total proteins and fucosylated glycoproteins (Fig. S4, A and B). To prove that secreted radioactivity comes from newly synthesized proteins and not from the material detaching from the cells, we used brefeldin A (BFA), an inhibitor of vesicle membrane trafficking (Helms and Rothman, 1992). Treatment with BFA almost completely prevented the secretion of fucosylated proteins, confirming applicability of the designed approach (Fig. S4 B). In addition, we demonstrated that after  $\sim 2$  h, all the labeled material is secreted (Fig. S4 B). This was further confirmed by analyzing the secretion of glycoproteins containing  $^3\text{H}$ -fucose after 2 h pulse labeling of HepG2 cells, where all the label material is secreted within  $\sim 90$  min (Fig. S4 C).

We used HepG2, Huh7, and CHO cells pre-labeled with  $^{13}\text{C}$ -UL-Fucose to measure the contributions of each source of fucose to secreted, fucosylated N-glycans. For both HepG2 and




Figure 1. **Cells selectively utilize fucose derived from mannose and glucose as well as fucose originating from an exogenous source. (A)** Schematic showing the biosynthetic pathways involved in GDP-fucose production. **(B and E)** Incorporation of 5 mM <sup>13</sup>C-UL-glucose, 50 μM <sup>13</sup>C-3,4-mannose and <sup>13</sup>C-6-

fucose into fucosylated N-glycans produced by HeLa, HepG2, Huh7 and CHO cells expressed as a percentage of labeling (B) or as a percentage of maximal signal (E);  $n = 3$ ; data are presented as mean  $\pm$  SD. (C) Schematic representation of the results presented in panel B. (D) Comparison of GDP-fucose amount produced by HepG2, CHO, and Huh7 treated and untreated with exogenous fucose. Statistical significance was assigned using two-tailed  $t$  test; ns,  $P > 0.05$ ;  $n = 5$ ; data are presented as mean  $\pm$  SD.

Huh7, the contributions of salvage and de novo pathways are comparable in the absence of fucose<sup>Ex</sup>. In contrast, CHO cells rely more heavily on the salvage pathway. As previously observed, fucose<sup>Ex</sup> quickly suppresses the de novo pathway. However, utilization of fucose<sup>Sal</sup> is much less sensitive to fucose<sup>Ex</sup> (Fig. 2, A and B).

We found that fucose<sup>Man</sup> is, once again, less sensitive to fucose<sup>Ex</sup> than fucose<sup>Glc</sup>. Fucose<sup>Sal</sup> is treated differently; its contribution changes very little, i.e., decreases only by 10–40% when exposed to fucose<sup>Ex</sup> (Fig. 2 C). This confirms that cells can distinguish and preferentially incorporate GDP-fucose of one heritage over another. This is compatible with the existence of separate GDP-fucose pools in the cytoplasm.

### Fucose linkage drives the selectivity between different GDP-fucose pools

We investigated the utilization of different GDP-fucose sources in N-glycosylation by first analyzing the contribution of fucose<sup>Ex</sup> to N-glycans with one and two fucose residues. In N-glycans with a single fucose, this monosaccharide is predominantly attached to the chitobiose core as  $\alpha$ 1-6 fucose and is referred to as core fucosylation. Only one fucose residue can be attached to the chitobiose core; all others must reside on N-glycan antennae, which is linked to N-acetylglucosamine via  $\alpha$ 1-3 or  $\alpha$ 1-4 linkage or to galactose via  $\alpha$ 1-2 linkage.

First, we compared the incorporation efficiency of exogenous <sup>13</sup>C-UL-fucose to <sup>12</sup>C-fucose that originated from endogenous sources i.e., salvage or de novo pathway (fucose<sup>Endo</sup>) using NanoHPLC Chip-Q-TOF MS (Park et al., 2017; Song et al., 2015; Wong et al., 2020). We investigated the labeling pattern of a series of 9–45 different bifucosylated N-glycans (the number varied depending on the cell line). Since each of these N-glycans must have two fucose residues it can either incorporate two residues of <sup>12</sup>C-fucose (M+0), two residues of <sup>13</sup>C-UL-fucose (M+12), or one of each (M+6). We expected an increase in label incorporation that is proportional to fucose<sup>Ex</sup> concentration.

We labeled seven different cell lines with increasing concentrations of exogenous <sup>13</sup>C-UL-Fucose for 24 h and analyzed the N-glycans produced by these cells. As expected, we observed a dose-dependent incorporation of <sup>13</sup>C-UL-Fucose into N-glycans with a single fucose residue until we reached a plateau and then maximized the incorporation of fucose<sup>Ex</sup> by 24 h (Fig. 3 A and Fig. S4 D). Unexpectedly, for those N-glycans with two fucoses, the first fucose, which we believe is predominantly the core fucose, requires less fucose<sup>Ex</sup> to become labeled than the second one. At low fucose<sup>Ex</sup> concentration (0–10  $\mu$ M), the first fucose residue originates from fucose<sup>Ex</sup>, while the second uses fucose<sup>Endo</sup>. Replacing both <sup>12</sup>C-fucoses with <sup>13</sup>C-UL-Fucose requires more accessible fucose<sup>Ex</sup> (Fig. 3 A and Fig. S4 D). This suggests fucose in different linkages and added by various fucosyltransferases, localized in different Golgi compartments, relies on distinct GDP-fucose pools.

These results are incompatible with a single, homogenous GDP-fucose pool in the cytoplasm, further confirming our hypothesis.

Next, we used lectins that specifically recognize fucose in different linkages: LCA recognizes  $\alpha$ 1-6 fucose (core), LTL recognizes  $\alpha$ 1-3 and  $\alpha$ 1-4 fucose, UEA1 recognizes  $\alpha$ 1-2 fucose, and AAL recognizes all these linkages with variable efficiencies. We analyzed the incorporation of fucose<sup>Ex</sup> into different positions in glycans using cells with chemically or genetically inactivated de novo pathways (see Materials and methods). We chose the cell lines HepG2, CaCo<sub>2</sub>, HCT116, HEK293, and the CHO mutant Lec30 as they exhibited high binding to LTL and/or UEA1. Once again, we found that  $\alpha$ 1-6 fucose (chitobiose core) requires less fucose<sup>Ex</sup> to become maximally labeled than  $\alpha$ 1-2,  $\alpha$ 1-3, and  $\alpha$ 1-4 fucose (antennae; Fig. 3, B and C), confirming the results of the above <sup>13</sup>C-UL-Fucose labeling experiments.

A limitation of the lectin-based approach is that it requires inhibition of the de novo pathway and only focuses on fucose<sup>Ex</sup> utilization. Therefore, we searched for alternative methods to assess the incorporation of fucose<sup>Ex</sup> into different positions of N-glycans by using cells with a functional de novo pathway. First, we used GC-MS to compare the incorporation of <sup>13</sup>C-UL-fucose<sup>Ex</sup> into N-glycans produced by CHO and CHO-Lec30 cells as well as Huh7 and Huh7 FUT8 knock-out cells. FUT8 is the only fucosyltransferase capable of adding fucose to the chitobiose core of N-glycans (Yang and Wang, 2016) and is the only fucosyltransferase adding fucose to N-glycans, which is expressed in wild-type CHO cells. CHO-Lec30 is a gain-of-function mutant cell line that additionally expresses FUT4 and FUT9 that fucosylates N-glycan antennae (North et al., 2010; Patnaik and Stanley, 2006). If all fucosyltransferases had similar access to different GDP-fucose sources, CHO-Lec30 and Huh7 FUT8 knock-out cells would incorporate comparable amounts of fucose<sup>Ex</sup> to wild-type CHO and Huh7 cells, respectively. However, we found that both CHO-Lec30 and Huh7 FUT8 knock-out cells rely on fucose<sup>Endo</sup> much more than wild-type CHO and Huh7 respectively, which incorporated significantly higher amounts of fucose<sup>Ex</sup> into their N-glycans (Fig. 3, D and E). This supports our hypothesis on distinct preferences between different GDP-fucose sources among various fucosyltransferases. It also shows that the efficient incorporation of fucose<sup>Ex</sup> into the N-glycan chitobiose core is not due to FUT8 having better access to GDP-fucose than other fucosyltransferases that modify the N-glycan antennae.

To confirm linkage specificity, we used an LC-MS approach to analyze N-glycans released from HepG2-secreted proteins labeled with exogenous <sup>13</sup>C-UL-Fucose (Fig. S5). Among all applied approaches, this is the only method that allowed us to directly investigate fucose linkage. Analysis of the three most abundant secreted N-glycans with a single  $\alpha$ 1-6 fucose showed a similar trend in fucose<sup>Ex</sup> incorporation compared to cell-associated material analyzed with NanoHPLC Chip-Q-TOF MS (Fig. 4 A and Fig. 3 A). The same was true when we assessed the







Figure 2. **The contribution of fucose salvage into N-glycans is almost insensitive to exogenous fucose.** (A and C) Incorporation of 5 mM  $^{13}\text{C}$ -1,2-glucose, 50  $\mu\text{M}$   $^{13}\text{C}$ -1,2,3-mannose and  $^{13}\text{C}$ -6-fucose into fucose associated with newly synthesized N-glycoproteins secreted by HepG2, Huh7, and CHO cells pre-labeled for 11 d with 50  $\mu\text{M}$   $^{13}\text{C}$ -UL-fucose expressed as a percentage of labeling (A) and as a percentage of maximal signal (C);  $n = 3$ ; data are presented as mean  $\pm$  SD. (B) Schematic representation of the results are presented in A.

incorporation of fucose<sup>Ex</sup> into the two most abundant N-glycans with two fucoses, where the first fucose requires less fucose<sup>Ex</sup> to become labeled compared to the second one (Fig. 4 A). To investigate which fucose residue is preferentially labeled with fucose<sup>Ex</sup>, we performed the MS/MS analysis of bifucosylated N-glycans, which only incorporated a single molecule of fucose<sup>Ex</sup> (Fig. S5). This allowed us to compare the positions where

$^{13}\text{C}$ -fucose<sup>Ex</sup> and  $^{12}\text{C}$ -fucose<sup>Endo</sup> are incorporated in N-glycans, determining if there is any preference toward the incorporation of either of them into N-glycan chitobiose core vs. antennae. If there was an equal preference for incorporating fucose<sup>Ex</sup> to N-glycan core and antennae, there would be a similar distribution of  $^{13}\text{C}$ -labeled between both fragments of N-glycan. However, we found that fucose<sup>Ex</sup> is more efficiently incorporated into



**Figure 3. Various fucose linkages exhibit different preference to exogenous fucose.** (A) LC-MS analysis of exogenous  $^{13}\text{C}$ -UL-L-fucose incorporation into cell-associated N-glycans produced by HepG2, HeLa, and CHO cells that have only one fucose residue as well as N-glycans with two fucoses; M+6 refers to N-glycans which incorporated a single molecule of exogenous fucose; M+12 refers to N-glycans which incorporated two molecules of exogenous fucose; data are presented as mean  $\pm$  SEM; N refers to the number of unique N-glycan structures. (B) Lectin staining of HepG2, CaCo2, HCT116, HEK293, and CHO-Lec30 cells that have chemically or genetically inactivated *de novo* pathway, treated with increasing concentrations of exogenous fucose;  $n = 3$ ; data are presented as mean  $\pm$  SD. (C) Schematic representation of the results presented in B. (D) GC-MS analysis of exogenous  $^{13}\text{C}$ -UL-fucose incorporation efficiency into fucose associated with cellular N-glycoproteins as well as newly synthesized N-glycoproteins secreted by CHO and CHO-Lec30 cells expressed as a percentage of labeling;  $n = 3$ ; data are presented as mean  $\pm$  SD. (E) GC-MS analysis of exogenous  $^{13}\text{C}$ -UL-fucose incorporation into fucose associated with cell associated N-glycoproteins as well as newly synthesized N-glycoproteins secreted by Huh7 and Huh7 FUT8 knock-out cells;  $n = 3$ ; data are presented as mean  $\pm$  SD.

the chitobiose core, while fucose<sup>Endo</sup> is preferentially incorporated into the antennae (Fig. 4, B and C). Altogether, this again confirms preferential utilization of GDP-fucose originating from the fucose<sup>Ex</sup> by FUT8, while fucose<sup>Endo</sup> is used by fucosyltransferases located in the trans-Golgi to modify N-glycan antennae.

### Different glycoprotein acceptors rely on distinct GDP-fucose sources

Next, we characterized the contribution of different GDP-fucose sources into O-fucosylation of epidermal growth factor (EGF)-like repeats and ThromboSpondin type 1 Repeats (TSRs), which occur in the ER and are performed by GDP-fucose protein




Figure 4. **Core fucose preferentially rely on exogenous fucose while fucose attached to N-glycan antennae utilizes endogenous fucose more efficiently.** (A) MALDI-TOF analysis of exogenous  $^{13}\text{C}$ -UL-fucose incorporation into N-glycans that have only one fucose residue as well as N-glycans with two

fucose residues, produced by HepG2 cells; M+6 refers to N-glycans which incorporated a single molecule of exogenous fucose; M+12 refers to N-glycans which incorporated two molecules of exogenous fucose;  $n = 2$ ; data are presented as mean  $\pm$  SD. **(B)** LC-MS analysis of exogenous  $^{13}\text{C}$ -UL-fucose and endogenous  $^{12}\text{C}$ -fucose incorporation into N-glycans produced by HepG2 cells with two fucose residues. Black bars indicate N-glycans with endogenous  $^{12}\text{C}$ -fucose incorporated into both chitobiose core and antennae. Green bars indicate N-glycans with exogenous  $^{13}\text{C}$ -UL-fucose incorporated into chitobiose core and endogenous  $^{12}\text{C}$ -fucose into antennae. Blue bars indicate N-glycans with exogenous  $^{13}\text{C}$ -UL-fucose incorporated into antennae and endogenous  $^{12}\text{C}$ -fucose into chitobiose core. Red bars for N-glycans with exogenous  $^{13}\text{C}$ -UL-fucose into both chitobiose core and antennae;  $n = 2$ ; data are presented as mean  $\pm$  SD; statistical analysis was performed using two-tailed  $t$  test;  $P > 0.1$  ns;  $P < 0.1^*$ . **(C)** Schematic representation of the results presented in B.

O-fucosyltransferases (POFUTs). The former reaction is catalyzed by POFUT1, while the latter by POFUT2 (Fig. 5 A). Both enzymes catalyze chemically identical reactions and only differ in recognized acceptors/glycoproteins. Over 100 proteins, including Notch, contain the EGF-like repeat consensus sequence required for POFUT1 O-fucosylation, and  $\sim 50$  proteins contain a TSRs consensus sequence for POFUT2 O-fucosylation (Schneider et al., 2017).

We used Huh7 cells pre-labeled with  $^{13}\text{C}$ -6-fucose overexpressing recombinant proteins containing either NOTCH1 EGF-like repeats 1–5, where repeats 2, 3, and 5 have a single O-fucose modification, or a recombinant protein containing thrombospondin 1 TSRs 1–3, where all three TSRs carry an O-fucose modification. These proteins were purified using affinity cobalt resin, and their purity was confirmed by SDS-PAGE (Fig. 5 B). If both POFUTs had the same access to various GDP-fucose pools, they would rely on them to a comparable extent. However, we found that POFUT1 relies more on GDP-fucose originating from a fucose<sup>Ex</sup> as well as fucose<sup>Sal</sup>, compared to POFUT2, which has a stronger preference for GDP-fucose from the de novo pathway (Fig. 5, C and D). In addition, we did not observe any difference in the sensitivity of fucose<sup>Man</sup> and fucose<sup>Glc</sup> to fucose<sup>Ex</sup>, in contrast to N-glycoproteins, which are fucosylated in the Golgi. For POFUT1 and POFUT2, these sources are treated comparably (Fig. 5 E). When analyzing secreted material that did not bind to the affinity cobalt resin, we found that overexpression of EGF-like repeats or TSRs does not alter the normal fucosylation of N-glycans (Fig. 5, C and E). This experiment also demonstrated that N-glycan-linked fucose relies on various GDP-fucose pools to a different extent compared to O-linked fucose. Altogether, the data show that different fucosyltransferases and various glycoproteins utilize distinct GDP-fucose sources and confirms our hypothesis on the presence of separate, non-homogenous GDP-fucose pools in the cytoplasm.

## Discussion

The results presented here support our hypothesis that the metabolic origin of fucose determines its use for glycosylation and suggests that GDP-fucose resides in multiple, distinct pools. We can simultaneously distinguish the contributions of exogenous, salvaged, and de novo sources to global N-glycosylation and that of individual glycoproteins. It is broadly accepted that these sources contribute to a single, homogenous pool, and little is known about the interplay between these pathways. There are multiple reports on the biosynthesis of nucleotides and lipids that compare the contribution of the de novo biosynthesis to exogenous precursors, but they never simultaneously address all biosynthetic routes (Moitra et al., 2021; Nieto et al., 2008; Wu

et al., 2020; Zhang et al., 2019). In contrast, for nucleotide sugars, there is only a limited number of studies addressing this problem. In addition to the studies from the 1970s on the contributions of glucose, mannose, and exogenous fucose into GDP-fucose (Yurchenco and Atkinson, 1975; Yurchenco and Atkinson, 1977), it has been demonstrated that exogenous mannose and exogenous galactose can overcome de novo-produced GDP-mannose and UDP-galactose, respectively, when provided in sufficient concentration (Ichikawa et al., 2014; Radenkovic et al., 2019).

The pioneering studies performed in HeLa cells concluded that 90% of GDP-fucose is derived from the de novo pathway used only a single fucose<sup>Ex</sup> concentration, 0.3  $\mu\text{M}$  (Yurchenco and Atkinson, 1975; Yurchenco and Atkinson, 1977). In dose-response experiments, we showed that fucose<sup>Ex</sup> is the preferential source of N-glycan-associated fucose, gradually suppressing the de novo pathway without increasing the total cytoplasmic concentration of GDP-fucose. It agrees with previous experiments in HepB3 cells showing that 100  $\mu\text{M}$  fucose<sup>Ex</sup> does not increase GDP-fucose (Moriwaki et al., 2007). Suppression of the de novo pathway is likely due to feedback inhibition of GMDS with GDP-fucose, previously shown for *E. coli* and human enzymes (Kornfeld and Ginsburg, 1966; Sullivan et al., 1998). We also looked at the contribution of fucose<sup>Man</sup> and fucose<sup>Glc</sup> in N-glycan-associated fucose. Since increasing concentrations of fucose<sup>Ex</sup> do not affect glucose and mannose contribution in N-glycan-associated mannose, we would expect that fucose<sup>Ex</sup> affects them equally. However, that is not the case, and we observe that fucose<sup>Man</sup> is less sensitive to fucose<sup>Ex</sup> than fucose<sup>Glc</sup>. It indicates that different, non-homogenous pools of both GDP-fucose and GDP-mannose may exist in the cytoplasm. Since the overall size of the GDP-fucose pool remains constant, the (presumably) separate pools must be in communication. While this may be driven by changes in subcellular distribution of the biosynthetic enzymes, clearly, feedback inhibition of GMDS by GDP-fucose must be the mechanism.

Little is known about monosaccharides salvage since most studies equate it with an exogenous substrate. Analysis of N-acetylneuraminic acid (Neu5Ac) recycling using cells from individuals with Salla disease (Aula et al., 2000), which characterize it with dysfunctional SLC17A5 lysosomal transporter and are unable to recycle Neu5Ac (Ghosaini et al., 1988), demonstrated the importance of this process in sialylation (Chigorno et al., 1996). A single study using a lysosomal inhibitor  $\text{NH}_4\text{Cl}$  acidifying lysosomal lumen and causing a dysfunction of glycosylases demonstrated that N-acetylglucosamine (GlcNAc) and N-acetylgalactosamine (GalNAc) are also efficiently reutilized from glycoconjugates (Rome and Hill, 1986). We investigated the contribution of fucose<sup>Sal</sup> into fucosylation, while simultaneously






Figure 5. Various fucosyltransferases, which fucosylate different glycoproteins, exhibit distinct preference to different GDP-fucose sources. (A) Schematic showing POFUT1 and POFUT2 dependent glycosylation of EGF-like repeats and TSRs. (B) Coomassie Brilliant Blue G250 staining of

representative SDS-PAGE gel of purified recombinant EGF-like repeats and TSRs secreted for 12 h by Huh7 cells. Red arrows indicate the protein of interest. **(C and E)** Incorporation of 5 mM  $^{13}\text{C}$ -1,2-glucose, 50  $\mu\text{M}$   $^{13}\text{C}$ -1,2,3-mannose, and  $^{13}\text{C}$ -6-fucose into fucose associated with EGF-like repeats or TSRs secreted by Huh7 cells pre-labeled for 11 d with 50  $\mu\text{M}$   $^{13}\text{C}$ -UL-fucose expressed as a percentage of labeling (C) and a percentage of maximal signal (E);  $n = 2$  (for POFUT1 and POFUT2) and  $n = 4$  (for unbound N-glycans); data are presented as mean  $\pm$  SD. **(D)** Schematic representation of the results presented in C. Source data are available for this figure: SourceData F5.

analyzing its interplay with other GDP-fucose sources. In the absence of fucose<sup>Ex</sup>, ~50% of N-glycan-associated fucose originated from fucose<sup>Sal</sup> and another ~50% came from the de novo pathway. In contrast to the de novo pathway, salvage is almost completely insensitive to fucose<sup>Ex</sup>, and its contribution is hardly changed by increasing fucose<sup>Ex</sup> concentrations. Since the total cytoplasmic concentration of GDP-fucose does not change much upon the exposition to fucose<sup>Ex</sup>, there has to be a mechanism regulating the contribution of fucose<sup>Sal</sup>. However, further studies are needed to understand how fucose<sup>Ex</sup> selectively inhibits the salvage pathway as both sources of GDP-fucose utilize the same biosynthetic machinery. To our knowledge, our study is the first to define and quantify the contributions of exogenous vs. salvaged monosaccharides, so there are no reliable precedents. Huh7 and HepG2 are professional secretory cells, sending a substantial portion of newly synthesized glycoproteins into the plasma. By comparison, CHO cells secrete much less glycoprotein and are likely engineered to preferentially recycle fucose.

Fucosylation of N-glycan chitobiose core is catalyzed by FUT8 and occurs in the early medial-Golgi (Stanley, 2011), while antenna fucosylation happens in the trans-Golgi as well as trans-Golgi network (Brito et al., 2008; Buffone et al., 2013; Sousa et al., 2004). Fucose<sup>Ex</sup> is more efficiently incorporated into the N-glycans chitobiose core than into antenna. Since the addition of fucose<sup>Ex</sup> does not change the size of GDP-fucose pools, this observation cannot be explained by differences in a  $K_m$  between distinct fucosyltransferases. Analysis of FUT8 knock-out cells disproves that the preference of fucose<sup>Ex</sup> by FUT8 is simply due to its utilization of the GDP-fucose pool before it becomes accessible to other fucosyltransferases (i.e., FUT4, FUT9). If that were true, elimination of FUT8 would make the GDP-fucose originating from fucose<sup>Ex</sup> more accessible to other fucosyltransferases. Instead, it decreases the overall utilization of fucose<sup>Ex</sup>. We believe that separate Golgi compartments have different access to various GDP-fucose pools.

In the ER, POFUT1 and POFUT2 add a single O-fucose residue to EGF-like repeats and TSRs, respectively (Schneider et al., 2017). O-fucosylation of a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) proteins performed by POFUT2 is required for their secretion as it was shown for ADAMTS9, ADAMTS13, and ADAMTS20 (Benz et al., 2016; Holdener et al., 2019; Ricketts et al., 2007). O-fucosylation of Notch, conducted by POFUT1, is required for the activation of Notch by its ligand (Shi and Stanley, 2003). This shows the importance of O-fucosylation in a variety of biological processes. We looked at the utilization of various GDP-fucose pools by POFUT1 and POFUT2, demonstrating that POFUT1 exhibits a significantly higher preference toward the exogenous and salvaged substrate and POFUT2 more efficiently utilizes de novo-produced GDP-fucose. It indicates that fucosyltransferases for

O-glycans are located outside the Golgi, and modifying distinct glycoproteins also relies on separate GDP-fucose pools. The only possible explanation for this observation is the existence of separate, non-homogenous GDP-fucose pools in the cytoplasm. It is highly probable that the ER and Golgi have differential access to the GDP-fucose originating from various sources. This would also be true in the case of distinct Golgi stacks as we observe that FUT8, located in the early medial Golgi, has a stronger preference toward fucose<sup>Ex</sup> compared to the fucosyltransferases occupying trans Golgi stacks. Altogether, it suggests that different GDP-fucose pools are accessible to the ER, medial Golgi, and trans Golgi. How separate pools would be generated and maintained in the cells remains unclear. We do not believe that they are separated from each other through their allocation inside a membrane-delimited structure. Our hypothesis is that monosaccharides have distinct ways of cell entry and handling within the cell, contributing to the GDP-fucose pool segregation. Furthermore, each pathway utilizes various enzymes for GDP-fucose biosynthesis that could support nucleotide sugar segregation. In this scenario, each pool exists due to an increase in local GDP-fucose concentration and is variably accessible to a limited number of fucosyltransferases and protein acceptors. We suggest that GDP-fucose biosynthetic enzymes form functional complexes, and their association, as well as their subcellular distribution is influenced by fucose<sup>Ex</sup> concentration. However, it is unclear how it could regulate this process and it is important to point out that non-homogeneous GDP-fucose pools remain hypothetical.

Directly visualizing multiple intracellular GDP-fucose pools in living cells that show real-time responses to metabolic perturbations would certainly strengthen our claims. We have considered various indirect approaches, such as designing highly specific GDP-fucose sensors similar to that described for UDP-GlcNAc (Li et al., 2021) that show spatial responses to alterations of exogenous or salvaged fucose. Similar metabolic perturbations might also affect the distribution/association of their biosynthetic enzymes visualized by Förster resonance energy transfer (FRET) or proximity ligation analysis. This may indicate whether spatial and/or kinetic factors predominate.

A study on exogenous N-azidoacetylglucosamine (GlcNAz) incorporation into N-glycans showed that this GlcNAc analog is efficiently added into the antennae, but not into the chitobiose core (Shajahan et al., 2020). The former process occurs in the Golgi and the latter in the ER membrane. It may suggest that there is a preference for one source of UDP-GlcNAc over the other during different stages of N-glycan biosynthesis. The other possible explanation is that different GlcNAc transferases may have various preferences toward UDP-GlcNAc and UDP-GlcNAz. Recent studies on glycogen metabolism in the brain demonstrated that it serves as a reservoir for multiple glycoconjugates.

Disruption of its metabolism causes a global decrease in free pools of UDP-GlcNAc and N-glycosylation (Sun et al., 2021). These studies are consistent with our proposed model of distinct pools of the same nucleotide sugar existing in the cytosol, where one pool is preferred over another by different glycosyltransferases.

To summarize, we presented a novel concept of selective utilization of different monosaccharide sources using fucose as a model sugar. Our research can only be explained by separate, non-homogenous pools of nucleotide sugars in the cytoplasm, and each makes a specific contribution to glycosylation processes. Various glycoproteins and distinct glycosyltransferases rely on different nucleotide sugar pools, and this selectivity is regulated by the access of exogenous/dietary monosaccharides. However, further efforts are required to explain how such pools are formed and sustained. We think that it is worthwhile to expand this concept beyond glycosylation and verify it for other metabolic precursors.

## Materials and methods

### Cell culture

HepG2, Huh7, HEK293, HeLa, HCT116, CaCo2, and A549 (ATCC) cells were grown in complete 1 g/l (5.5 mM) glucose containing Dulbecco's modified Eagle's medium (Corning) supplemented with 10% heat-inactivated fetal bovine serum (Sigma-Aldrich), 100 U/ml penicillin and 10 mg/ml streptomycin (GIBCO), and 2 mM L-glutamine. CHO, CHO-Lec13, and CHO-Lec30 were grown in complete Ham's F-12K (Kaighan's) medium with 7 mM glucose (Corning) supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin and 10 mg/ml streptomycin, and 2 mM L-glutamine. For metabolic labeling purposes, cells were grown in glucose-free Dulbecco's modified Eagle's medium (Gibco) supplemented with 5 mM glucose, 50  $\mu$ M mannose, and 0–50  $\mu$ M fucose, 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin and 10 mg/ml streptomycin, and 2 mM L-glutamine. Glucose, mannose, and fucose were variously replaced with equimolar  $^{13}\text{C}$  substrates as noted in the next section. In the case of CHO, CHO-Lec13, and CHO-Lec30 labeling medium was additionally supplemented with 0.6 mM L-proline as these cell lines are auxotrophic for proline. Studies on secreted N-glycans or glycoproteins were performed using cells growing in a serum-free medium.

### Metabolic labeling

To analyze the contribution of different monosaccharides to glycosylation, cells were grown in different combinations of  $^{13}\text{C}$ -glucose,  $^{13}\text{C}$ -mannose, and  $^{13}\text{C}$ -fucose. In each experiment, the number of heavy carbons varied between glucose, mannose, and fucose substrates. The following sugars were used in this study:  $^{13}\text{C}$ -5-glucose (M+1),  $^{13}\text{C}$ -1,2-glucose (M+2),  $^{13}\text{C}$ -UL-glucose (M+6),  $^{13}\text{C}$ -4-mannose (M+1),  $^{13}\text{C}$ -3,4-mannose (M+2),  $^{13}\text{C}$ -1,2,3-mannose (M+3),  $^{13}\text{C}$ -UL-mannose (M+6),  $^{13}\text{C}$ -6-fucose (M+1), and  $^{13}\text{C}$ -UL-fucose (M+6). To analyze fucose salvage, cells were pre-labeled with either  $^{13}\text{C}$ -6-fucose (M+1) or  $^{13}\text{C}$ -UL-fucose (M+6) by growing them for 11 d in a complete medium containing 50  $\mu$ M  $^{13}\text{C}$ -fucose. This allowed for the substitution of

90–95% of N-glycan-associated fucose with  $^{13}\text{C}$ -fucose. To distinguish between salvaged and exogenous  $^{13}\text{C}$ -fucose, fucose<sup>Sal</sup> carried a different number of heavy carbons compared to fucose<sup>Ex</sup>. All  $^{13}\text{C}$ -labeled monosaccharides were purchased from Omicron Biochemicals.

### GC-MS analysis and sample preparation

Cells were labeled with  $^{13}\text{C}$ -sugars for 12 h, washed twice with DPBS, scraped, and centrifuged for 3 min at 1,600 rpm. Cell pellets were sonicated in 50 mM sodium phosphate buffer, pH 7.5, containing 40 mM DTT, incubated at 100°C, cooled down, and sonicated again. PNGase F was added to the resulting cell lysate and samples were incubated overnight at 37°C. For analysis of secreted N-glycans, HepG2 cells were labeled for 6 h before collecting the medium, while Huh7 and CHO were labeled for 12 h. Serum-free medium was concentrated using 3 kD cut-off filters (Sigma-Aldrich). Next, the buffer was changed to 50 mM sodium phosphate buffer, pH 7.5, using the same filters. The concentrated medium was collected from the filters and, after addition of PNGase F, samples were incubated overnight at 37°C.

Released N-glycans were purified with TopTip 10–200  $\mu$ l carbon columns (PolyLC, Inc.). All columns were prewashed using 1  $\times$  200  $\mu$ l 80% acetonitrile solution with 0.1% TFA, 1  $\times$  200  $\mu$ l 50% acetonitrile solution with 0.05% TFA, and 1  $\times$  200  $\mu$ l 3% acetonitrile solution with 0.05% TFA, followed by equilibration using 2  $\times$  200  $\mu$ l water. Each time the solution was removed from the columns by centrifuging for 5 min at 5,000 rpm. Cell samples were centrifuged for 20 min at 14,000 rpm and the resulting supernatant was loaded onto the columns. Medium samples were directly loaded onto the columns. After loading the samples, the columns were subsequently washed twice with 200  $\mu$ l of water and twice with 200  $\mu$ l of 3% acetonitrile solution with 0.05% TFA. Glycans were eluted with 3  $\times$  200  $\mu$ l 50% acetonitrile solution with 0.05% TFA and dried in a SpeedVac.

Dried N-glycans were hydrolyzed in 2 N TFA (Sigma Aldrich) at 100°C for 2 h to release monosaccharides, and the cooled samples were again dried in a SpeedVac. If both fucose and mannose were analyzed, the hydrolyzed sample was equally divided. Samples were stored in –20°C and derivatized immediately before GC-MS analysis.

To analyze the contribution of glucose and mannose into N-glycan-associated mannose, hydrolyzed samples were dissolved in 10  $\mu$ l water and 50  $\mu$ l of 50 mg/ml hydroxylamine hydrochloride (Sigma-Aldrich) in 1-methyl-imidazole (Sigma-Aldrich) was added. Samples were incubated at 80°C for 10 min. After cooling for 10 min, 100  $\mu$ l of acetic anhydride (Sigma-Aldrich) was added to the samples, followed by 100  $\mu$ l of chloroform (Honeywell) and subsequent addition of 200  $\mu$ l of water. Samples were vigorously vortexed for 10–15 s and centrifuged for 10 min at 14,000 rpm. Next, the top layer (aqueous) was discarded and 200  $\mu$ l of water was added to the organic phase. Samples were again mixed, centrifuged, and the aqueous layer was discarded. The organic layer was dried in a SpeedVac, re-suspended in pyridine (Chem-Impex Int'l, Inc.), and analyzed with GC-MS. GC-MS analysis was done using a 15 m  $\times$  0.25 mm  $\times$

0.25- $\mu\text{m}$  Rxi-5ms column (Restek) on a QP2010 Plus GC-MS. Detector sensitivity and  $m/z$  range were optimized for each sample set separately. Electron impact was used for MS ion fragmentation. GC-MS ion fragment intensities were quantified using GC-MS Solution version 2.5o SU3 from Shimadzu Corp. Each fragment was corrected for the natural abundance of each element using matrix-based probabilistic methods as described (Nanchen et al., 2007; van Winden et al., 2002). The contribution of glucose and mannose to mannose was calculated from the fragment  $m/z$  314 (Ichikawa et al., 2014).

To analyze the contribution of glucose, mannose, and fucose to N-glycan-associated fucose, hydrolyzed samples were derivatized initially in 20 mg/ml pyridine solution of *O*-(2,3,4,5,6-Pentafluorobenzyl) hydroxylamine hydrochloride (PFBO; Alfa Aesar) and incubated for 20 min at 80°C. After cooling, an equal volume of *N,O*-Bis(trimethylsilyl)trifluoroacetamide (BSTFA; Sigma-Aldrich) was added, and the samples were incubated for an additional 60 min at 80°C. Derivatized samples were analyzed by GC-MS using the instrument and column described above, but with negative chemical ionization using methane as the reagent gas. The GC-MS was programmed with an injection temperature of 250°C, 2  $\mu\text{l}$  injection volume, and a split ratio of 1/10. The GC oven temperature was initially 160°C for 4 min, rising to 230°C at 6°C/min, then to 280°C at 60°C/min with a final hold at this temperature for 2 min. GC flow rate with helium carrier gas was 50 cm/s. The GC-MS interface temperature was 300°C and (NCI) ion source temperature was 200°C. Detector sensitivity and  $m/z$  range were optimized for each sample set separately. The contribution of glucose, mannose, and fucose to fucose was calculated from the fragments with  $m/z$  376 and 466 (respectively,  $\text{C}_{15}\text{H}_{34}\text{O}_4\text{NSi}_3$ —loss of pentafluorobenzene plus trimethylsilyl-OH, and  $\text{C}_{18}\text{H}_{44}\text{O}_5\text{NSi}_4$ —loss of pentafluorobenzene; Fig. S1, A–C). Same as for mannose, GC-MS ion fragment intensities were quantified using GC-MS Solution version 2.5o SU3 from Shimadzu Corp, and each fragment was corrected for the natural abundance of each element using matrix-based probabilistic methods as described (Nanchen et al., 2007; van Winden et al., 2002). To ensure the accuracy of the data analysis process, we always performed control experiments with cells growing in 5 mM  $^{12}\text{C}$ -glucose and 50  $\mu\text{M}$   $^{12}\text{C}$ -mannose and compared the isotopic distribution on M+0 to M+6 positions between  $^{12}\text{C}$ - and  $^{13}\text{C}$ -labeled samples. In addition, we used HCT116 and CHO-Lec13 cells, which are GMDS null mutants that do not produce GDP-fucose de novo, and therefore do not utilize glucose or mannose for fucosylation. We did not see a significant contribution of glucose metabolism products to fucosylation.

### **$^{35}\text{S}$ methionine/cysteine labeling**

HepG2 cells seeded on 6-cm plates and at 70% confluency were washed twice with DPBS. Next, labeling complete Dulbecco's modified Eagle's medium without methionine (Corning) supplemented with 0.2 mCi  $^{35}\text{S}$  Met/ml (1,000 Ci/mmol; 3:1 mix of Met and Cys; cat #ARS 0110A; American Radiolabeled Chemicals, Inc.) was added. After 2 h of labeling, the cells were washed five times with DPBS, and the medium was replaced with serum-free medium containing 10-fold excess of cold Met (300 mg/l). The medium was collected after 0, 15, 30 min, 1, 1.5,

2, 3 or 6 h of incubation. To analyze label incorporation into proteins, 100  $\mu\text{l}$  of the medium was mixed with 200  $\mu\text{g}$  of bovine serum albumin. An equal volume of 20% TCA was added to each sample and incubated on ice for 20 min then centrifuged at 14,000 rpm for 15 min at 4°C. Precipitated proteins were washed twice with 1 ml of ice-cold acetone and centrifuged at 14,000 rpm for 15 min at 4°C after each wash. Excess acetone was evaporated by incubating the samples for 1 h at room temperature under an ambient atmosphere. To reconstitute proteins, 100  $\mu\text{l}$  of 2% SDS was added, and samples were sonicated and incubated for 15 min in 100°C. Then 10% of the resulting solution was counted in a scintillation counter.

### **[5, 6- $^3\text{H}$ ]-fucose labeling**

HepG2 cells were seeded on six-well plates and at 70% confluency. They were washed twice with DPBS and after that, 0.5 ml of labeling complete Dulbecco's modified Eagle's medium was added to each well. Labeling medium contained 5  $\mu\text{M}$  cold fucose and 15  $\mu\text{Ci}$  of L-[5,6- $^3\text{H}$ ]-fucose (40–60 Ci/mmol; 1 mCi/ml; cat #ART0106A; American Radiolabeled Chemicals, Inc.). After 2 h, the cells were washed five times with DPBS, and the medium was replaced with serum-free medium containing 5  $\mu\text{M}$  cold fucose. Medium and the cells were collected after 0, 15, 30, 60, 120, or 180 min of incubation. Before collecting cells, they were washed five times with DPBS, scraped, and lysed in 2% SDS. Then 50% of the collected material was counted using a scintillation counter.

### **LCA pull down**

LCA agarose beads (Vector Laboratories) were equilibrated by washing five times with 10 mM HEPES buffer, pH 7.5, with 0.15 M NaCl, 0.1 mM  $\text{CaCl}_2$ , and 1 mM  $\text{MnCl}_2$ . Next, 100  $\mu\text{l}$  of medium sample was diluted with 900  $\mu\text{l}$  of equilibration buffer and incubated with 30  $\mu\text{l}$  of beads overnight with rotation at 4°C. Subsequently, the beads were washed five times with the equilibration buffer. Between each step, samples were centrifuged for 5 min, 1,000  $\times g$ , 4°C, and the fractions were saved for further analysis. To elute fucosylated N-glycans, 200  $\mu\text{l}$  of 2% SDS was added to the beads and the samples were heated at 100°C for 10 min. The solution was then centrifuged for 15 min at 14,000 rpm and transferred to a fresh tube. Then 10% of each fraction was counted in a scintillation counter.

### **FUT8 knock-out in Huh7 cells**

The guide RNA sequence 5'-CAGAATTGGCGCTATGCTAC-3' targeting exon 7 of *FUT8* was cloned into px458 pSpCas9(BB)-2A-GFP (Addgene). The resulting plasmid was transfected into Huh7 cells using ViaFect (Promega) transfection reagent following the manufacturer's instructions. After 48 h of transfection, GFP-positive cells were FACS-sorted using a FACS ARIA IIu instrument (BD Biosciences) into 96-well plates to generate isogenic clones, which were expanded and screened by Sanger sequencing with a forward primer 5'-GCTGGTGTGTAATATCAA CA-3' and reverse primer 5'-GTATGTTCCATGAAGGTCTAC-3'. Two isogenic clones were identified carrying different homozygous mutations in *FUT8* (NM\_178155.2). Clone 3 harbored a c.732\_762del [p.E244Dfs\*9] and clone 20 a c.753dupT



[p.T252Yfs\*9]. FUT8 deficiency was confirmed in Western blot using a Fut8-specific antibody (cat #66118-1-Ig; Proteintech). The glycosylation defect was confirmed with LCA and AAL lectins (Vector Laboratories). Clone 3 was used in further analysis.

### Isolation and quantitative HPLC analysis of nucleotide sugars

To measure the amount of GDP-fucose in cells, cytoplasmic nucleotide sugars were isolated using a modified protocol described by Nakajima et al. (2010). A total of 500 pmol of UDP-arabinose, an internal standard, was added before workup. We chose UDP-arabinose since it does not occur in mammalian cells and has a unique retention time in the elution gradient (Fig. S2 A). Linear response of authentic GDP-fucose was confirmed between 40 and 500 pmol (Fig. S2 B).

Briefly, cells were grown on 10-cm plates to 70–80% confluency. For the last 6 h (HepG2) or 12 h (Huh7 and CHO), they were grown in the presence or absence of 50  $\mu$ M fucose. Cells were scraped in DPBS and centrifuged for 3 min at 1,500 rpm. The resulting cell pellet was washed twice with cold DPBS. Next, 1 ml of 70% ice-cold ethanol containing 500 pmol of UDP-arabinose was added to the cell pellet. Cells were sonicated and centrifuged at 16,000  $\times$  *g* for 10 min at 4°C to remove insoluble material. The supernatant was lyophilized and the pellet was used to determine protein concentration using BCA Protein Assay Kit (Pierce). Dried supernatant was dissolved in 1 ml of 5 mM ammonium bicarbonate and purified on a 3-ml porous graphitic carbon column (EnviCarb; Sigma Aldrich—Supelco) equilibrated with 2 ml of 80% acetonitrile solution with 0.1% TFA and 2 ml of water. After loading the sample, the column was sequentially washed: 2 ml of water, 2 ml of 25% acetonitrile solution, 2 ml of water, 2 ml of 50 mM triethylammonium acetate buffer, pH 7.0, and 2 ml of water. Nucleotide sugars were eluted with 2 ml of 25% acetonitrile solution in 50 mM triethylammonium acetate buffer, pH 7.0, and lyophilized. Samples were stored at –80°C and analyzed within 12–48 h after the isolation.

Nucleotide sugars were separated using Inertsil ODS-4 250  $\times$  4.6 mm column with a particle size of 3  $\mu$ m (GL Science) and Vanquish Flex HPLC system (Thermo Fisher Scientific), with 100 mM potassium phosphate buffer, pH 6.4, containing 8 mM tetrabutylammonium hydrogen sulfate as buffer A and 70% solution of buffer A in 30% acetonitrile as buffer B. The separation method was as follows: buffer A for 13 min, linear gradient of 100–33% buffer A for 22 min, linear gradient of 33–0% buffer A for 1 min, 100% B for 14 min, and linear gradient of 0–100% A for 1 min. The flow rate was 0.8 ml/min and the separation temperature was 23°C. Nucleotide sugars were detected using a UV detector and absorption  $\lambda_{254}$ .

### NanoHPLC Chip-Q-TOF MS analysis

HepG2, CHO, CHO-Lec30, CaCo<sub>2</sub>, HeLa, HEK293, A549, and HCT116 cells were labeled for 24 h with increasing concentrations of <sup>13</sup>C-UL-Fucose, washed three times with DPBS, scraped, and centrifuged for 3 min at 1,600 rpm. The resulting cell pellets were stored at –80°C. N-glycans were isolated and analyzed as described by Wong et al. (2020). Cell pellets were

sonicated in 20 mM HEPES buffer, pH 7.5, containing 0.25 M sucrose and 1:100 protease inhibitor cocktail set V (Calbiochem) and centrifuged at 2,000  $\times$  *g* for 10 min to pellet nuclear fraction. Next, lysates were centrifuged in an ultracentrifuge at 200,000  $\times$  *g* for 45 min. The resulting pellets were dissolved in 100  $\mu$ l of 100 mM phosphate buffer, pH 7.0, containing 5 mM DTT and incubated in 100°C for 1 min to denature the proteins. To release N-glycans 2  $\mu$ l of PNGase F (New England Biolabs) was added and the samples were incubated for 18 h at 37°C. After that, they were ultracentrifuged at 200,000  $\times$  *g* for 45 min and supernatants containing free N-glycans were purified on porous graphitized carbon columns and dried in SpeedVac.

Agilent 6520 Accurate Mass Q-TOF LC/MS system with a microfluid porous graphitized carbon chip (Agilent) was used to analyze N-glycans composition. The binary gradient consisted of 0.1% of formic acid with 3% acetonitrile in water as buffer A and 1% formic acid with 89% acetonitrile in water was used to separate samples. The separation method was as followed: 100% of A for 2.5 min, linear gradient of 0–16% B for 17.5 min, and linear gradient of 16–58% B for 15 min, at a constant flow rate of 0.3  $\mu$ l/min. For data acquisition, the Q-TOF MS was set to acquire only MS1 in positive ionization mode with a cycle time of 1.5 s. To assist with compound identification, control samples were also run with collision-induced dissociation using nitrogen gas. Four MS2 spectra were obtained for every MS1 through data-dependent acquisition, with a total cycle time of 5.25 s. The mass range was set at 600–2,000 *m/z*. The instrument was calibrated with the ESI tuning mix commercially available from Agilent.

To analyze the data, we first identified peaks with Agilent MassHunter B.07 software using the existing library described by Wong et al. (2020). From the exported data, we created a new library containing the chemical formula and retention times of identified N-glycans for targeted isotope extraction. We used the Batch Isotopologue Analysis function of Agilent Profinder B.08 software to extract quantitative isotopolog data for each fucosylated N-glycan we identified. The program averages the MS signals across a chosen peak in an extracted ion chromatogram to form the MS spectra from which the isotopolog signals are extracted. It also corrects for the natural distribution of <sup>13</sup>C and returns the relative abundance of each isotopolog. Mass tolerance was set at  $\pm$  (10 ppm + 2 mDa) to screen out background noise or signals from other co-eluting compounds. For each glycan, the percent abundance of each isotopolog signal from M + 0 to M + 6 or M +12 was exported for further analysis.

### High throughput fucosylation analysis with lectins

Before the experiment, HepG2, CaCo<sub>2</sub>, HEK293, and CHO-Lec30 cells were grown for 48 h in the presence of 20  $\mu$ M Fucostatin II (Amgen), which is a small molecule inhibitor of GMDS (Fig. 1 A) and blocks the de novo production of GDP-fucose (Allen et al., 2016). Preincubated cells were seeded on 96-well black flat bottom plates (Falcon) in the presence of 20  $\mu$ M Fucostatin II. After 32 h, the medium was replaced with a fresh medium containing increasing concentrations of fucose and 20  $\mu$ M Fucostatin II. Cells were incubated with fucose for another 16 h and analyzed by immunofluorescence staining as described in the

next paragraph. The experimental procedure was identical for HCT116 cells, except Fucostatin II was not added since these cells are GMDS-deficient and lack a functional de novo pathway.

Cells were washed twice with DPBS, incubated for 15 min with 4% paraformaldehyde, washed three times with DPBS, and blocked with Carbo Free Blocking Solution (Vector Laboratories) in DPBS. After 1 h of blocking, biotinylated lectins (Vector Laboratories) were diluted in a blocking solution containing 1 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, and 1 mM MnCl<sub>2</sub> and added for 1 h. LCA and AAL were diluted at 1:500, while LTL and UEAI were diluted at 1:100. Cells were washed three times with DPBS and incubated for 1 h with Cy3-labeled streptavidin (Vector Laboratories) diluted 1:100 (LTL and UEAI) or 1:500 (LCA and AAL) in blocking solution. DAPI (Thermo Fisher Scientific) was then added directly to the solution at a final dilution 1:1,000. After 20 min, cells were washed three times in DPBS and 100 µl of DPBS was added to each well, and the plates were sealed with adhesive plate tape (Thermo Fisher Scientific).

Cells were analyzed immediately using IC200 microscope (Vala Sciences) and an air 20× objective. For each well, data were collected from four to six different focal areas. For data analysis, Acapella software (PerkinElmer) was used. The data were expressed as an average ratio of Cy3 fluorescence intensity to DAPI fluorescence intensity for at least 500 cells/well.

#### MALDI-TOF-MS and LC-MS/MS analysis

HepG2 cells were washed six times with DPBS and grown for 6 h in serum-free medium with increasing concentrations of UL-<sup>13</sup>C-fucose. The medium was collected and concentrated using 3 kD cut-off filters and repeatedly exchanged with 50 mM sodium phosphate buffer, pH 7.5, using the same filters. The concentrated medium was collected from the filters and 3 µl of PNGase F (New England Biolabs) was added to each sample and then incubated at 37°C for 24 h. Following incubation, samples were cooled to room temperature and passed through 10-kD Amicon Ultra centrifuge filters at 16,000 × *g* for 15 min. A total of 450 µl of 50 mM ammonium bicarbonate was added to the filters and samples were again centrifuged. Flow-through was collected and passed through a C18 SPE cartridge (Resprep). N-glycans were eluted with 3 ml of 5% acetic acid and lyophilized.

Per-O-methylation was performed using a dimethylsulfoxide (DMSO)/sodium hydroxide (NaOH) base. The base was made by combining 100 µl 50% NaOH and 200 µl methanol in a glass tube. Then 4 ml of anhydrous DMSO was added to the solution and mixed vigorously. The solution was then centrifuged at 3,000 × *g* for 5 min. White precipitated solid formed on the top of the solution as well as all remaining DMSO was removed. This process was repeated until the white precipitate no longer formed. The resulting base gel material at the bottom of the tube was then mixed with 1 ml of DMSO. Samples were reconstituted in 200 µl DMSO and then 300 µl of base solution was added. To this, 100 µl iodomethane was added and samples were mixed using a shaker for 15 min. A total of 2 ml LC-MS grade water was then added to quench the reaction, followed by 2 ml dichloromethane. The solution was mixed vigorously for 30 s and then centrifuged at 3,000 × *g* for 2 min. The upper water layer was removed and another 2 ml of water was added. This process was

repeated four times. The lower layer was then transferred to a clean glass tube and dried under N<sub>2</sub> stream. Dried samples were reconstituted in 20 µl methanol for MALDI-TOF-MS and LC-MS/MS analysis.

For MALDI analysis, 2 µl of the per-O-methylated N-glycans was mixed with 2 µl of DHB matrix (15 mg/ml in 70/30/0.1 acetonitrile/water/formic acid). The sample was then spotted on a MALDI plate and allowed to dry. Samples were analyzed using an AB Sciex TOF/TOF 5800 mass spectrometer in reflector mode. MALDI-TOF-MS data was analyzed using Data Explorer software and GlycoWorkBench.

Per-O-methylated N-glycans were mixed in 50/50 MeOH/H<sub>2</sub>O for LC-MS/MS analysis. Samples were analyzed on a Thermo Fisher Scientific Orbitrap Fusion Tribrid mass spectrometer equipped with a nanospray ion source and connected to a Dionex binary solvent system (Waltham). Prepacked nano-LC columns of 15 cm in length with 75 µm internal diameter filled with 3 µm C18 material (reverse phase) were used for chromatographic separation of the glycans. LC-MS/MS runs were conducted for 72 min using a sodiated buffer system (Buffer A: 1 mM NaOAc in H<sub>2</sub>O, Buffer B: 80% ACN, 0.1% formic acid, 1 mM NaOAc). Precursor ion scan was acquired at 120,000 resolution in the Orbitrap analyzer, and the precursors at a time frame of 3 s were selected for subsequent MS/MS fragmentation in the Orbitrap analyzer at 15,000 resolution. MS/MS fragmentation was conducted with fixed CID (Collision Energy 40%) using a data-dependent scan (DDS) program, which performs an MS/MS acquisition for the most abundant ions in the MS<sup>1</sup> spectrum. MS<sup>3</sup> experiments were performed using a targeted approach, where an MS<sup>3</sup> event was triggered when specific fragment ions (*m/z* 1,084, 1,209, 1,614, 1,802) were noted in the MS/MS spectrum. Precursors with an unknown charge state or charge state of + 1 were excluded, and dynamic exclusion was enabled (30 s duration). LC-MS/MS data were analyzed using Thermo Fisher FreeStyle and GlycoWorkBench.

#### Overexpression and purification of POFUT1 and POFUT2 substrates

Huh7 cells were seeded on 10-cm plates and grown to 70% confluency. They were transfected with either mN1 EGF1-5 myc His × 6 in pSecTag2 that encodes EGF-like repeats or hTSP1 TSR1-3 myc His × 6 in pSecTag2 that encodes TSR using ViaFect transfection reagent following the manufacturer's instructions. To transfect each plate, we used 10 µg of DNA and 20 µl of the transfection reagent.

Within 24 h after the transfection, cells were washed four times with DPBS, and the medium was replaced with 5 ml of serum-free labeling medium. After 12 h, medium was collected and recombinant proteins were purified on TALON metal affinity resin (Takara). 200 µl of the resin was loaded onto 1 ml column (Bio-Rad) and washed three times with 1 ml of 100 mM TBS buffer, pH 8.5, with 0.5 M NaCl and 5 mM imidazole. Next, the medium was diluted with an equal volume of 2 × equilibration buffer and loaded on the column. The resin was washed three times with 1 ml of equilibration buffer. Unbound material and all the washes were collected to the 15 ml tube and concentrated on 3 kD cut-off filters as described for medium

samples in the section GC-MS analysis and sample preparation. Proteins were eluted using 1 ml 100 mM TBS buffer, pH 8.5, with 0.5 M NaCl and 0.3 M imidazole and concentrated on 3 kD cut-off filters. To remove imidazole and exchange buffers, 450  $\mu$ l of 10 mM Hepes, pH 7.0, was run through the filter for five times. After the sample was collected from the filter, 10% was loaded on the 15% SDS-PAGE gel. To visualize purified proteins, gels were stained with 0.5% Coomassie Brilliant Blue G250 solution in 50% methanol and 10% acetic acid, which were washed out with 10% acetic acid. The remaining 90% of the sample was lyophilized and hydrolyzed with 2 N TFA. After drying, the samples were stored at  $-20^{\circ}\text{C}$  until GC-MS analysis. Acid hydrolysis, derivatization, and GC-MS analysis were performed as described in the previous section.

### Statistical analysis

For data statistical analysis, a two-tailed *t* test was employed. All analyses were performed with GraphPad Prism (GraphPad Software, La Jolla, CA). Statistical significance was assigned as indicated in the figure legends.

### Online supplemental material

[Fig. S1](#) shows additional information on mannose, glucose, and fucose incorporation into N-glycan-associated fucose. [Fig. S2](#) shows the HPLC analysis of GDP-fucose pool size. [Fig. S3](#) provides additional information on mannose and glucose incorporation into N-glycan-associated mannose. [Fig. S4](#) shows how newly synthesized proteins are secreted and how exogenous fucose is incorporated into different positions of N-glycan. [Fig. S5](#) provides additional information on MALDI-TOF-MS and LC-MS/MS analysis of N-glycans secreted by HepG2 cells.

### Acknowledgments

We would like to thank Dr. Pamela Stanley (Albert Einstein College of Medicine, New York, NY) for providing us with CHO, CHO-Lec13, and CHO-Lec30 cells. We would like to thank Jamie Smolin for her assistance. We would like to thank Amgen for providing Fucostatin II. We would like to thank Dr. Robert Coffman, Dr. Paul Atkinson, and Dr. Christopher Newgard for their critical reviews. We would like to thank Dr. Nathan Lewis and Dr. Saratram Gopalakrishnan for the collaboration on systems biology approach to study the kinetics of the formulation of GDP-fucose pools.

The Rocket Fund and National Institutes of Health grant R01DK099551 awarded to H.H. Freeze, GM061126 awarded to R.S. Haltiwanger, S10OD018530 and R24GM137782 awarded to P. Azadi, and R01GM049077 awarded to C.B. Lebrilla who supported this work. P. Sosicka was supported by Frontiers in Congenital Disorders of Glycosylation Career Developmental Award U54 NS115198. The Sanford Burnham Prebys Cancer Metabolism Core was supported by Cancer Center Support grant P30CA030199 from the National Cancer Institute.

The authors declare no competing financial interests.

Author contributions: Conceptualization, P. Sosicka, and H.H. Freeze; methodology, P. Sosicka, B.G. Ng, L.E. Pepi, A. Shajahan, M. Wong, D.A. Scott, K. Matsumoto, Z.-J. Xia, C.B.

Lebrilla, R.S. Haltiwanger, P. Azadi, and H.H. Freeze; investigation, P. Sosicka, B.G. Ng, L.E. Pepi, A. Shajahan, M. Wong, D.A. Scott, K. Matsumoto, and Z.-J. Xia; supervision, C.B. Lebrilla, R.S. Haltiwanger, P.A., and H.H. Freeze; writing—original draft, P. Sosicka, H.H. Freeze, and B.G. Ng; writing—review & editing, all authors.

Submitted: 6 May 2022

Revised: 14 July 2022

Accepted: 16 August 2022

### References

- Allen, J.G., M. Mujacic, M.J. Frohn, A.J. Pickrell, P. Kodama, D. Bagal, T. San Miguel, E.A. Sickmier, S. Osgood, A. Swietlow, et al. 2016. Facile modulation of antibody fucosylation with small molecule fucostatin inhibitors and cocrystal structure with GDP-mannose 4, 6-dehydratase. *ACS Chem. Biol.* 11:2734–2743. <https://doi.org/10.1021/acschembio.6b00460>
- Aula, N., P. Salomäki, R. Timonen, F. Verheijen, G. Mancini, J.E. Månsson, P. Aula, and L. Peltonen. 2000. The spectrum of SLC17A5-gene mutations resulting in free sialic acid-storage diseases indicates some genotype-phenotype correlation. *Am. J. Hum. Gen.* 67:832–840. <https://doi.org/10.1086/303077>
- Benz, B.A., S. Nandadasa, M. Takeuchi, R.C. Grady, H. Takeuchi, R.K. LoPilato, S. Kakuda, R.P.T. Somerville, S.S. Apte, R.S. Haltiwanger, and B.C. Holdener. 2016. Genetic and biochemical evidence that gastrulation defects in Pofut2 mutants result from defects in ADAMTS9 secretion. *Dev. Biol.* 416:111–122. <https://doi.org/10.1016/j.ydbio.2016.05.038>
- Brito, C., S. Kandzia, T. Graça, H.S. Conradt, and J. Costa. 2008. Human fucosyltransferase IX: Specificity towards N-linked glycoproteins and relevance of the cytoplasmic domain in intra-Golgi localization. *Biochimie.* 90:1279–1290. <https://doi.org/10.1016/j.biochi.2008.03.002>
- Buffone, A., Jr., N. Mondal, R. Gupta, K.P. McHugh, J.T.Y. Lau, and S. Neelamegham. 2013. Silencing  $\alpha$ 1, 3-fucosyltransferases in human leukocytes reveals a role for FUT9 enzyme during E-selectin-mediated cell adhesion. *J. Biol. Chem.* 288:1620–1633. <https://doi.org/10.1074/jbc.M112.400929>
- Chigorno, V., G. Tettamanti, and S. Sonnino. 1996. Metabolic processing of gangliosides by normal and Salla human fibroblasts in culture. A study performed by administering radioactive GM3 ganglioside. *J. Biol. Chem.* 271:21738–21744. <https://doi.org/10.1074/jbc.271.36.21738>
- Coffey, J.W., O.N. Miller, and O.Z. Sellinger. 1964. The metabolism of L-fucose in the rat. *J. Biol. Chem.* 239:4011–4017. [https://doi.org/10.1016/s0021-9258\(18\)91124-5](https://doi.org/10.1016/s0021-9258(18)91124-5)
- Ghosaini, L.R., A.M. Brown, and J.M. Sturtevant. 1988. Scanning calorimetric study of the thermal unfolding of catabolite activator protein from *Escherichia coli* in the absence and presence of cyclic mononucleotides. *Biochemistry.* 27:5257–5261. <https://doi.org/10.1021/bi00414a046>
- Ginsburg, V. 1960. Formation of guanosine diphosphate L-fucose from guanosine diphosphate D-mannose. *J. Biol. Chem.* 235:2196–2201. [https://doi.org/10.1016/s0021-9258\(18\)64598-3](https://doi.org/10.1016/s0021-9258(18)64598-3)
- Gonzalez, P.S., J. O'Prey, S. Cardaci, V.J.A. Barthet, J.I. Sakamaki, F. Beaumatin, A. Roseweir, D.M. Gay, G. Mackay, G. Malviya, et al. 2018. Mannose impairs tumour growth and enhances chemotherapy. *Nature.* 563:719–723. <https://doi.org/10.1038/s41586-018-0729-3>
- Helms, J.B., and J.E. Rothman. 1992. Inhibition by brefeldin A of a Golgi membrane enzyme that catalyzes exchange of guanine nucleotide bound to ARF. *Nature.* 360:352–354. <https://doi.org/10.1038/360352a0>
- Holdener, B.C., C.J. Percival, R.C. Grady, D.C. Cameron, S.J. Berardinelli, A. Zhang, S. Neupane, M. Takeuchi, J.C. Jimenez-Vega, S.M.Z. Uddin, et al. 2019. ADAMTS9 and ADAMTS20 are differentially affected by loss of B3GLCT in mouse model of Peters plus syndrome. *Hum. Mol. Gen.* 28:4053–4066. <https://doi.org/10.1093/hmg/ddz225>
- Ichikawa, M., D.A. Scott, M.E. Losfeld, and H.H. Freeze. 2014. The metabolic origins of mannose in glycoproteins. *J. Biol. Chem.* 289:6751–6761. <https://doi.org/10.1074/jbc.M113.544064>
- Ishihara, H., D.J. Massaro, and E.C. Heath. 1968. The metabolism of L-fucose. 3. The enzymatic synthesis of  $\beta$ -L-fucose 1-phosphate. *J. Biol. Chem.* 243:1103–1109. [https://doi.org/10.1016/s0021-9258\(19\)56958-7](https://doi.org/10.1016/s0021-9258(19)56958-7)



- Kaufman, R.L., and V. Ginsburg. 1968. The metabolism of L-fucose by HeLa cells. *Exp. Cell Res.* 50:127–132. [https://doi.org/10.1016/0014-4827\(68\)90400-x](https://doi.org/10.1016/0014-4827(68)90400-x)
- Kornfeld, R.H., and V. Ginsburg. 1966. Control of synthesis of guanosine 5'-diphosphate D-mannose and guanosine 5'-diphosphate L-fucose in bacteria. *Biochim. Biophys. Acta.* 117:79–87. [https://doi.org/10.1016/0304-4165\(66\)90154-1](https://doi.org/10.1016/0304-4165(66)90154-1)
- Li, Z., J. Zhang, and H.W. Ai. 2021. Genetically encoded green fluorescent biosensors for monitoring UDP-GlcNAc in live cells. *ACS Cent. Sci.* 7:1763–1770. <https://doi.org/10.1021/acscentsci.1c00745>
- Lu, L., X. Hou, S. Shi, C. Körner, and P. Stanley. 2010. Slc35c2 promotes Notch1 fucosylation and is required for optimal Notch signaling in mammalian cells. *J. Biol. Chem.* 285:36245–36254. <https://doi.org/10.1074/jbc.M110.126003>
- Lühn, K., M.K. Wild, M. Eckhardt, R. Gerardy-Schahn, and D. Vestweber. 2001. The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. *Nat. Gen.* 28:69–72. <https://doi.org/10.1038/ng0501-69>
- Moitra, S., S. Basu, M. Pawlowic, F.F. Hsu, and K. Zhang. 2021. De novo synthesis of phosphatidylcholine is essential for the promastigote but not amastigote stage in leishmania major. *Front. Cell. Infect. Microbiol.* 11:647870. <https://doi.org/10.3389/fcimb.2021.647870>
- Moriwaki, K., K. Noda, T. Nakagawa, M. Asahi, H. Yoshihara, N. Taniguchi, N. Hayashi, and E. Miyoshi. 2007. A high expression of GDP-fucose transporter in hepatocellular carcinoma is a key factor for increases in fucosylation. *Glycobiology.* 17:1311–1320. <https://doi.org/10.1093/glycob/cwm094>
- Nakajima, K., S. Kitazume, T. Angata, R. Fujinawa, K. Ohtsubo, E. Miyoshi, and N. Taniguchi. 2010. Simultaneous determination of nucleotide sugars with ion-pair reversed-phase HPLC. *Glycobiology.* 20:865–871. <https://doi.org/10.1093/glycob/cwq044>
- Nanchen, A., T. Fuhrer, and U. Sauer. 2007. Determination of metabolic flux ratios from 13C-experiments and gas chromatography-mass spectrometry data: Protocol and principles. *Methods Mol. Biol.* 358:177–197. [https://doi.org/10.1007/978-1-59745-244-1\\_11](https://doi.org/10.1007/978-1-59745-244-1_11)
- Nieto, F.L., L.G. Pescio, N.O. Favale, A.M. Adamo, and N.B. Sterin-Speziale. 2008. Sphingolipid metabolism is a crucial determinant of cellular fate in non-stimulated proliferating Madin-Darby canine kidney (MDCK) cells. *J. Biol. Chem.* 283:25682–25691. <https://doi.org/10.1074/jbc.M804437200>
- North, S.J., H.H. Huang, S. Sundaram, J. Jang-Lee, A.T. Etienne, A. Trollope, S. Chalabi, A. Dell, P. Stanley, and S.M. Haslam. 2010. Glycomics profiling of Chinese hamster ovary cell glycosylation mutants reveals N-glycans of a novel size and complexity. *J. Biol. Chem.* 285:5759–5775. <https://doi.org/10.1074/jbc.M109.068353>
- Park, D., G. Xu, M. Barboza, I.M. Shah, M. Wong, H. Raybould, D.A. Mills, and C.B. Lebrilla. 2017. Enterocyte glycosylation is responsive to changes in extracellular conditions: Implications for membrane functions. *Glycobiology.* 27:847–860. <https://doi.org/10.1093/glycob/cwx041>
- Patnaik, S.K., and P. Stanley. 2006. Lectin-resistant CHO glycosylation mutants. *Methods Enzymol.* 416:159–182. [https://doi.org/10.1016/S0076-6879\(06\)16011-5](https://doi.org/10.1016/S0076-6879(06)16011-5)
- Radenkovic, S., M.J. Bird, T.L. Emmerzaal, S.Y. Wong, C. Felgueira, K.M. Stiers, L. Sabbagh, N. Himmelreich, G. Poschet, P. Windmolders, et al. 2019. The metabolic map into the pathomechanism and treatment of PGMI-CDG. *Am. J. Hum. Gen.* 104:835–846. <https://doi.org/10.1016/j.ajhg.2019.03.003>
- Ricketts, L.M., M. Dlugosz, K.B. Luther, R.S. Haltiwanger, and E.M. Majerus. 2007. O-fucosylation is required for ADAMTS13 secretion. *J. Biol. Chem.* 282:17014–17023. <https://doi.org/10.1074/jbc.M700317200>
- Rome, L.H., and D.F. Hill. 1986. Lysosomal degradation of glycoproteins and glycosaminoglycans. Efflux and recycling of sulphate and N-acetylhexosamines. *Biochem. J.* 235:707–713. <https://doi.org/10.1042/bj2350707>
- Schneider, M., E. Al-Shareffi, and R.S. Haltiwanger. 2017. Biological functions of fucose in mammals. *Glycobiology.* 27:601–618. <https://doi.org/10.1093/glycob/cwx034>
- Shajahan, A., N.T. Supekar, H. Wu, A.M. Wands, G. Bhat, A. Kalimurthy, M. Matsubara, R. Ranzinger, J.J. Kohler, and P. Azadi. 2020. Mass spectrometric method for the unambiguous profiling of cellular dynamic glycosylation. *ACS Chem. Biol.* 15:2692–2701. <https://doi.org/10.1021/acscchembio.0c00453>
- Shi, S., and P. Stanley. 2003. Protein O-fucosyltransferase 1 is an essential component of Notch signaling pathways. *Proc. Natl. Acad. Sci. USA.* 100:5234–5239. <https://doi.org/10.1073/pnas.0831126100>
- Song, T., D. Aldredge, and C.B. Lebrilla. 2015. A method for in-depth structural annotation of human serum glycans that yields biological variations. *Anal. Chem.* 87:7754–7762. <https://doi.org/10.1021/acs.analchem.5b01340>
- Sousa, V.L., C. Brito, and J. Costa. 2004. Deletion of the cytoplasmic domain of human  $\alpha$ 3/4 fucosyltransferase III causes the shift of the enzyme to early Golgi compartments. *Biochim. Biophys. Acta.* 1675:95–104. <https://doi.org/10.1016/j.bbagen.2004.08.015>
- Stanley, P. 2011. Golgi glycosylation. *Cold Spring Harbor Perspect. Biol.* 3:a005199. <https://doi.org/10.1101/cshperspect.a005199>
- Sullivan, F.X., R. Kumar, R. Kriz, M. Stahl, G.Y. Xu, J. Rouse, X.J. Chang, A. Boodhoo, B. Potvin, and D.A. Cumming. 1998. Molecular cloning of human GDP-mannose 4, 6-dehydratase and reconstitution of GDP-fucose biosynthesis in vitro. *J. Biol. Chem.* 273:8193–8202. <https://doi.org/10.1074/jbc.273.14.8193>
- Sun, R.C., L.E.A. Young, R.C. Bruntz, K.H. Markussen, Z. Zhou, L.R. Conroy, T.R. Hawkinson, H.A. Clarke, A.E. Stanback, J.K.A. Macedo, et al. 2021. Brain glycogen serves as a critical glucosamine cache required for protein glycosylation. *Cell Metabol.* 33:1404–1417.e9. <https://doi.org/10.1016/j.cmet.2021.05.003>
- van Winden, W.A., C. Wittmann, E. Heinzle, and J.J. Heijnen. 2002. Correcting mass isotopomer distributions for naturally occurring isotopes. *Biotechnol. Bioeng.* 80:477–479. <https://doi.org/10.1002/bit.10393>
- Varki, A., R.D. Cummings, J.D. Esko, P. Stanley, G.W. Hart, M. Aebi, A.G. Darvill, T. Kinoshita, N.H. Packer, J.H. Prestegard, et al. 2015. Essentials of Glycobiology. In *Essentials of Glycobiology*. A. Varki, R.D. Cummings, J.D. Esko, P. Stanley, G.W. Hart, M. Aebi, A.G. Darvill, T. Kinoshita, N.H. Packer, J.H. Prestegard, R.L. Schnaar, and P.H. Seeberger, editors. Cold Spring Harbor Laboratory Press, New York.
- Verheijen, J., S. Tahata, T. Kozicz, P. Witters, and E. Morava. 2020. Therapeutic approaches in congenital disorders of glycosylation (CDG) involving N-linked glycosylation: An update. *Genet. Med.* 22:268–279. <https://doi.org/10.1038/s41436-019-0647-2>
- Wong, M., G. Xu, M. Barboza, I. Maezawa, L.W. Jin, A. Zivkovic, and C.B. Lebrilla. 2020. Metabolic flux analysis of the neural cell glycolyx reveals differential utilization of monosaccharides. *Glycobiology.* 30:859–871. <https://doi.org/10.1093/glycob/cwaa038>
- Wu, R., X. Chen, S. Kang, T. Wang, J.R. Gnanaprakasam, Y. Yao, L. Liu, G. Fan, M.R. Burns, and R. Wang. 2020. De novo synthesis and salvage pathway coordinately regulate polyamine homeostasis and determine T cell proliferation and function. *Sci. Adv.* 6:eabc4275. <https://doi.org/10.1126/sciadv.abc4275>
- Yang, Q., and L.X. Wang. 2016. Mammalian  $\alpha$ -1, 6-fucosyltransferase (FUT8) is the sole enzyme responsible for the N-acetylglucosaminyltransferase I-independent core fucosylation of high-mannose N-glycans. *J. Biol. Chem.* 291:11064–11071. <https://doi.org/10.1074/jbc.M116.720789>
- Yurchenco, P.D., and P.H. Atkinson. 1975. Fucosyl-glycoprotein and precursor pools in HeLa cells. *Biochemistry.* 14:3107–3114. <https://doi.org/10.1021/bi00685a011>
- Yurchenco, P.D., and P.H. Atkinson. 1977. Equilibration of fucosyl glycoprotein pools in HeLa cells. *Biochemistry.* 16:944–953. <https://doi.org/10.1021/bi00624a021>
- Zhang, J., J. Tao, Y. Ling, F. Li, X. Zhu, L. Xu, M. Wang, S. Zhang, C.E. McCall, and T.F. Liu. 2019. Switch of NAD salvage to de novo biosynthesis sustains SIRT1-RelB-dependent inflammatory tolerance. *Front. Immunol.* 10:2358. <https://doi.org/10.3389/fimmu.2019.02358>



## Supplemental material




Figure S1. **Analysis of mannose, glucose, and fucose incorporation into N-glycan-associated fucose.** (A) GC chromatogram of derivatized fucose. (B) MS fragmentation of fucose. Left panel, MS fragmentation of the peak with elution time 11.6 min. Right panel, MS fragmentation of the peak with elution time 11.7 min. (C) Chemical structure of fucose derivatized with BSTFA/PFBO before MS fragmentation. (D and E) Incorporation of 5 mM  $^{13}\text{C}$ -UL-glucose, 50  $\mu\text{M}$   $^{13}\text{C}$ -3,4-mannose and  $^{13}\text{C}$ -6-fucose into fucose associated with N-glycoproteins produced by A549, CaCo2, HEK293, HCT116 and CHO-Lec13 cells expressed as a percentage of labeling (D) or as a percentage of maximal signal (E); HCT116 and CHO-Lec13 are GMDS mutants with inactive de novo pathway;  $n = 3$ ; data are presented as mean  $\pm$  SD. (F and G) Incorporation of 5 mM glucose, 50  $\mu\text{M}$  mannose and fucose into fucose associated with N-glycoproteins produced by HepG2 cells expressed as a percentage of labeling (F) or as a percentage of maximal signal (G); monosaccharides with different number and position of  $^{13}\text{C}$  carbons were used to evaluate a possibility of kinetic isotope effect;  $n = 3$ ; data are presented as mean  $\pm$  SD. (H and I) Incorporation of 5 mM  $^{13}\text{C}$ -5,6-glucose, 50  $\mu\text{M}$   $^{13}\text{C}$ -4-mannose and  $^{13}\text{C}$ -UL-fucose into fucose associated with N-glycoproteins produced by HepG2 cells during 48 h labeling period expressed as a percentage of labeling (H) or as a percentage of maximal signal (I);  $n = 3$ ; data are presented as mean  $\pm$  SD.




Figure S2. **HPLC analysis of GDP-fucose pool size.** (A) HPLC separation of nucleotide and nucleotide sugar standards. (B) Standard curve presenting linear correlation between an amount of injected GDP-fucose and an area of the peak eluting from the column. (C) HPLC profile of nucleotide sugars isolated from HepG2, Huh7 and CHO cells untreated with fucose (black) and treated with 50  $\mu$ M fucose (red); green arrow indicates UDP-arabinose and red arrow indicates GDP-fucose. (D) Zoom into elution time that covers GDP-fucose only.




Figure S3. **Analysis of mannose and glucose incorporation into N-glycan-associated mannose.** Incorporation of 5 mM  $^{13}\text{C}$ -UL-glucose and 50  $\mu\text{M}$   $^{13}\text{C}$ -3,4-mannose into mannose associated with N-glycoproteins produced by HeLa, HepG2, Huh7, CHO, A549, CaCo<sub>2</sub>, HEK293, HCT116 and CHO-Lec13 cells expressed as a percentage of maximal signal;  $n = 3$ ; data are presented as mean  $\pm$  SD.






Figure S4. **Analysis of newly synthesized proteins secretion and incorporation of exogenous fucose into different positions in N-glycan.** (A) Secretion of  $^{35}\text{S}$  Met labeled, newly synthesized proteins and fucosylated glycoproteins (LCA bound) produced by HepG2 cells;  $n = 3$ ; data are presented as mean  $\pm$  SD. (B) Secretion of  $^{35}\text{S}$  Met labeled, newly synthesized, fucosylated glycoproteins, pulled down with LCA produced by HepG2 cells growing in a presence or absence of  $5\ \mu\text{g/ml}$  BFA;  $n = 3$ ; data are presented as mean  $\pm$  SD. (C) Secretion and intracellular utilization of  $^3\text{H}$ -fucose in pre-labeled HepG2 cells grown in a presence of  $10\ \mu\text{M}$  cold fucose;  $n = 3$ ; data are presented as mean  $\pm$  SD. (D) LC-MS analysis of exogenous  $^{13}\text{C}$ -UL-fucose incorporation into cell associated N-glycans produced by A549, CaCo<sub>2</sub>, HEK293 and CHO-Lec13 cells that have only one fucose residue as well as N-glycans with two fucose residues; M+6 refers to N-glycans which incorporated a single molecule of exogenous fucose; M+12 refers to N-glycans which incorporated two molecules of exogenous fucose; CHO-Lec13 cells are GMDS mutants with inactive de novo pathway; data are presented as mean  $\pm$  SEM; N refers to the number of unique N-glycan structures.




Figure S5. **MALDI-TOF-MS and LC-MS/MS analysis of N-glycans secreted by HepG2 cells.** **(A)** MALDI-TOF-MS analysis of N-glycans secreted by HepG2 cells, growing without  $^{13}\text{C}$ -UL-fucose. **(B)** MALDI-TOF-MS analysis of N-glycans secreted by HepG2 cells, growing in a presence of  $50\ \mu\text{M}$   $^{13}\text{C}$ -UL-fucose. **(C)** MALDI-TOF-MS distribution of  $^{12}\text{C}$ -fucose and  $^{13}\text{C}$ -UL-fucose for one representative N-glycan. **(D)** LC-MS<sup>3</sup> (m/z 1,334, m/z 1,209) analysis of a bifucosylated N-glycan from HepG2 cell growing in  $20\ \mu\text{M}$   $^{13}\text{C}$ -UL-fucose, which incorporated only one  $^{13}\text{C}$ -UL-fucose fucose residue. Inset zooms in on low m/z range.